Global pharma powerhouse Roche has secured a major regulatory win that could dramatically expand access to advanced diagnostic testing across U.S. laboratories.

 

The company has announced that the U.S. Food and Drug Administration has classified its Ionify steroid assays for mass spectrometry as “moderate complexity” under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) — a move that lowers the barrier for adoption beyond highly specialized labs.

 

Until now, mass spectrometry testing has largely been confined to expert-run facilities due to its technical complexity. 

 

Roche’s newly classified assays — including Estradiol, DHEA, DHEA-S, Progesterone, 17-Hydroxyprogesterone and Androstenedione — are designed to change that. Running on the cobas i 601 analyzer within the cobas Mass Spec solution, the system combines high analytical precision with a simplified, standardized workflow.

 

“This technology fundamentally transforms mass spectrometry, moving it from an intricate specialty process to a seamless engine for routine diagnostics,” said Brad Moore, President and CEO, Roche Diagnostics North America. 

 

“By delivering a broad and expanding mass spectrometry menu with automation and standardization, we are empowering laboratories to operate more efficiently and enabling clinicians to make critical decisions sooner – helping ensure the right treatment reaches the right patient without delay.”

 

The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio now eligible for broader clinical use under the “moderate complexity” designation. The shift is expected to allow more laboratories to perform sophisticated testing without requiring highly specialized personnel.

 

Roche says it is continuing to build out its mass spectrometry pipeline, with additional assays currently in development and under regulatory review — signaling a broader push to make high-end diagnostics more accessible and routine.